Description of Invention:
Many tumors and blood cell cancers show overactivation of the NF-kappa B signal transduction pathway. This overactivation is associated with cancer forming in the colon, liver and other epithelial sites. In addition, there is evidence that overactivation leads to tumor formation and metastasis. However, this pathway is key for normal immunity, so any inhibition of NF-kappa B overactivation must avoid diminishing the body’s ability to fight infection.
This invention claims a compound that inhibits NF-kappa B activation without affecting other transcription factors such as AP-1 and SRE binding proteins. It appears to function by blocking IKK beta and is effective at low micromolar concentrations without affecting cell proliferation or cell survival. At this low concentration, NF-kappa B is reduced to basal levels so this novel compound has prospects for preventing or treating cancer without being detrimental to immunity. In addition, because NF-kappa B overactivation contributes to a variety of inflammatory disorders including colitis, diabetes, prostatitis, and pancreatitis this compound has therapeutic applications beyond cancer.
Applications:
Therapeutic for the chemoprevention or treatment of cancers associated with the overactivation of NF-kappa B signaling pathway
Therapeutic for the treatment of inflammatory disorders related to NF-kappa B overactivation
Reagent for the diagnosis of conditions related to overexpression of NF-kappa B
Advantages:
Highly specific inhibitor that allows targeting NF-kappa B without inhibiting other transcription factors.
Effective at preventing carcinogenesis without affecting normal cell proliferation and survival.
Therapeutic for treatment of cancer that will not compromise the immune system.
Development Status:
Early stage
Market:
Cancer is the second leading cause of death in the U.S. and it is estimated that 1.4 million Americans develop cancer in a year.
Relevant Publication: None related to invention have been published.
Licensing Status: Available for exclusive or non-exclusive licensing.
Collaborative Research Opportunity:
The National Cancer Institute (SAIC-Frederick) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize around development of analogs and/or further investigations of mechanism of action of the compound. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
Portfolios: Internal Medicine Cancer
Cancer -Therapeutics-Conventional Chemotherapy-Other Cancer -Therapeutics Internal Medicine-Diagnostics
For Additional Information Please Contact: Sabarni K. Chatterjee Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: 301/435-5587
Email: chatterjeesa@mail.nih.gov
Fax: 301/402-0220
